title: Apart from the other members of PDE inhibitors' family, enoximone does not enhance renal ischemic reperfusion injury: the effects of enoximone on renal ischemia reperfusion.
abstract: Many pharmacological agents were investigated for the prevention of renal ischemic reperfusion (IR) injury as well as the phosphodiesterase (PDE) inhibitors. The aim of the study was to examine the possible renoprotective effect of enoximone as a member of this family on IR injury. Thirty-six Wistar-Albino rats were allocated to six groups. Sham (S) and control groups (E1, E2) only received 0.09% NaCl, 5 mg/kg and 10 mg/kg enoximone via caudal caval vein, respectively. In ischemia (I) and treatment groups (IE1, IE2), the rats were subjected to bilateral renal artery occlusion and were given 0.09% NaCl, 5 mg/kg and 10 mg/kg enoximone in the same route, respectively. Bilateral kidneys were removed at the sixth hour of laparotomy for histopathological and biochemical analysis, such as superoxide dismutase, myeloperoxidase, malonyldialdehyde, and nitric oxide end products. Blood samples were taken in order to evaluate renal function tests. The data were analyzed by using one-way analysis of variance, and p < .05 was considered to be statistically significant. The worst results were achieved in ischemia group (p < .05). Treatments groups showed nearly similar findings with this group (p < .05). There was no significant difference between control and sham groups. In this study, we found that apart from the other members of the PDE inhibitors' family, enoximone did not contribute to the attenuation of IR injury of kidney.
authors.affiliation: Gazi University, Faculty of Medicine, Department of Pediatric Surgery, Ankara, Turkey. ademirtola@yahoo.com
authors.forename: Arzu
authors.initials: A
authors.lastname: Pampal
authors.forename: I Onur
authors.initials: IO
authors.lastname: Ozen
authors.forename: Billur
authors.initials: B
authors.lastname: Demirogullari
authors.forename: I Hakki
authors.initials: IH
authors.lastname: Gol
authors.forename: M Meral
authors.initials: MM
authors.lastname: Guclu
authors.forename: Neslihan
authors.initials: N
authors.lastname: Bukan
authors.forename: Aylar
authors.initials: A
authors.lastname: Poyraz
authors.forename: Ramazan
authors.initials: R
authors.lastname: Karabulut
authors.forename: A Can
authors.initials: AC
authors.lastname: Basaklar
authors.forename: Nuri
authors.initials: N
authors.lastname: Kale
mesh_terms: D000818:Animals; D017335:Enoximone / Q000494:pharmacology / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000517:prevention & control*; D008297:Male; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*
chemical_list: D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone